353 related articles for article (PubMed ID: 18215735)
1. Iron chelators can protect against oxidative stress through ferryl heme reduction.
Reeder BJ; Hider RC; Wilson MT
Free Radic Biol Med; 2008 Feb; 44(3):264-73. PubMed ID: 18215735
[TBL] [Abstract][Full Text] [Related]
2. Desferrioxamine inhibits production of cytotoxic heme to protein cross-linked myoglobin: a mechanism to protect against oxidative stress without iron chelation.
Reeder BJ; Wilson MT
Chem Res Toxicol; 2005 Jun; 18(6):1004-11. PubMed ID: 15962935
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of heme protein redox cycling: reduction of ferryl heme by iron chelators and the role of a novel through-protein electron transfer pathway.
Roberts LJ
Free Radic Biol Med; 2008 Feb; 44(3):257-60. PubMed ID: 18067870
[No Abstract] [Full Text] [Related]
4. Tyrosine as a redox-active center in electron transfer to ferryl heme in globins.
Reeder BJ; Cutruzzola F; Bigotti MG; Hider RC; Wilson MT
Free Radic Biol Med; 2008 Feb; 44(3):274-83. PubMed ID: 18215736
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.
Bendova P; Mackova E; Haskova P; Vavrova A; Jirkovsky E; Sterba M; Popelova O; Kalinowski DS; Kovarikova P; Vavrova K; Richardson DR; Simunek T
Chem Res Toxicol; 2010 Jun; 23(6):1105-14. PubMed ID: 20521781
[TBL] [Abstract][Full Text] [Related]
6. Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity.
Hašková P; Koubková L; Vávrová A; Macková E; Hrušková K; Kovaříková P; Vávrová K; Simůnek T
Toxicology; 2011 Nov; 289(2-3):122-31. PubMed ID: 21864640
[TBL] [Abstract][Full Text] [Related]
7. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
8. A new sensitive assay reveals that hemoglobin is oxidatively modified in vivo.
Vollaard NB; Reeder BJ; Shearman JP; Menu P; Wilson MT; Cooper CE
Free Radic Biol Med; 2005 Nov; 39(9):1216-28. PubMed ID: 16214037
[TBL] [Abstract][Full Text] [Related]
9. Alternative treatment paradigm for thalassemia using iron chelators.
Szuber N; Buss JL; Soe-Lin S; Felfly H; Trudel M; Ponka P
Exp Hematol; 2008 Jul; 36(7):773-85. PubMed ID: 18456387
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine can protect against oxidative stress through ferryl hemoglobin reduction.
Lu N; He Y; Chen C; Tian R; Xiao Q; Peng YY
Toxicol In Vitro; 2014 Aug; 28(5):847-55. PubMed ID: 24698734
[TBL] [Abstract][Full Text] [Related]
11. Oxidation of low-density lipoprotein by hemoglobin stems from a heme-initiated globin radical: antioxidant role of haptoglobin.
Miller YI; Altamentova SM; Shaklai N
Biochemistry; 1997 Oct; 36(40):12189-98. PubMed ID: 9315856
[TBL] [Abstract][Full Text] [Related]
12. The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia.
Fibach E; Rachmilewitz EA
Ann N Y Acad Sci; 2010 Aug; 1202():10-6. PubMed ID: 20712766
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of low-density lipoprotein oxidation by hemoglobin-derived iron.
Grinshtein N; Bamm VV; Tsemakhovich VA; Shaklai N
Biochemistry; 2003 Jun; 42(23):6977-85. PubMed ID: 12795592
[TBL] [Abstract][Full Text] [Related]
14. Effects of glutathione, Trolox and desferrioxamine on hemoglobin-induced protein oxidative damage: anti-oxidant or pro-oxidant?
Lu N; Chen W; Peng YY
Eur J Pharmacol; 2011 Jun; 659(2-3):95-101. PubMed ID: 21419762
[TBL] [Abstract][Full Text] [Related]
15. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
Lim CK; Kalinowski DS; Richardson DR
Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of lipophilic iron chelators as protective agents from oxidative stress.
Yavin E; Kikkiri R; Gil S; Arad-Yellin R; Yavin E; Shanzer A
Org Biomol Chem; 2005 Aug; 3(15):2685-7. PubMed ID: 16032345
[TBL] [Abstract][Full Text] [Related]
17. Hemoglobin and myoglobin associated oxidative stress: from molecular mechanisms to disease States.
Reeder BJ; Wilson MT
Curr Med Chem; 2005; 12(23):2741-51. PubMed ID: 16305469
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
Rai BL; Dekhordi LS; Khodr H; Jin Y; Liu Z; Hider RC
J Med Chem; 1998 Aug; 41(18):3347-59. PubMed ID: 9719587
[TBL] [Abstract][Full Text] [Related]
19. Control of oxidative reactions of hemoglobin in the design of blood substitutes: role of the ascorbate-glutathione antioxidant system.
Simoni J; Villanueva-Meyer J; Simoni G; Moeller JF; Wesson DE
Artif Organs; 2009 Feb; 33(2):115-26. PubMed ID: 19178455
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance.
Liu G; Men P; Harris PL; Rolston RK; Perry G; Smith MA
Neurosci Lett; 2006 Oct; 406(3):189-93. PubMed ID: 16919875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
